<DOC>
	<DOC>NCT02676401</DOC>
	<brief_summary>This study aims to evaluate the safety and efficacy of MT-3995 administered over the longer term, following MT-3995-J05 study.</brief_summary>
	<brief_title>An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Written informed consent for participation before the completion of MT3995J05 Study Completion of MT3995J05 study UACR of ≥300 mg/g Cr with an increase of ≥30% in MT3995J05 Study Symptomatic and clinically significant hypotension QT prolongation or torsades de pointes New York Heart Association (NYHA) Class III or IV heart failure Patients who are judged to be unsuitable for participation based on their safety profile in MT3995J05 Study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>